Insight

Photo of Edward Cliff from hmpgloballearningnetwork.com

Jul 27, 2024, 14:57

Edward Cliff: The development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat

Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on X about a recent paper titled “US Food and Drug Administration’s Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma” published in Journal of Clinical Oncology.

Authors: Edward R. Scheffer Cliff, David A. Russler-Germain, C. Joseph Ross Daval and Aaron S. Kesselheim.

“In Journal of Clinical Oncology we review the development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat, and discuss strategies for FDA Oncology to deal with delayed confirmatory clinical trials.

Read here.”

Source: Edward Cliff/X

Aaron S. Kesselheim belinostat C. Joseph Ross Daval cancer David A. Russler-Germain Edward Cliff FDA Oncology Journal of Clinical Oncology OncoDaily Oncology Peter MacCallum Cancer Centre pralatrexate T-cell lymphoma The Royal Melbourne Hospital

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage